8.75 (-%)
As of Nov 20, 2024
Source:
We are a clinical-stage biotechnology company leveraging our novel targeted oncology platform to develop a potential new standard of care across multiple cancer indications, with an initial focus on ocular and urologic oncology. Our proprietary platform enables the targeting of a broad range of solid tumors using Virus-Like Particles, or VLPs, that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates, or VDCs. Our VDCs are largely agnostic to tumor type and can recognize a surface marker, known as heparan sulfate proteoglycans, or HSPGs, that are specifically modified and broadly expressed on many tumors.
Country | United States |
Headquarters | boston, massachusetts |
Phone Number | (617)500-8864 |
Industry | |
CEO | Elisabet De Los Pinos |
Website | www.clinicaltrials.gov |